Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer
Fracture risk after ARPI was high, exceeding 44% within 3 years in those with prior fractures despite BHA, suggesting limited benefit in patients with poor bone quality. Early identification and intervention for patients at high risk of fractures is critical.
Authors
- Kevin Zarrabi (ORCID: https://orcid.org/0000-0002-9351-2317)
- Amy L. Shaver (ORCID: https://orcid.org/0000-0002-0263-8708)
- Grace Lu‐Yao (ORCID: https://orcid.org/0000-0002-2925-7737)
- Christopher C. Yang (ORCID: https://orcid.org/0000-0001-5463-6926)
- Hushan Yang (ORCID: https://orcid.org/0000-0001-9920-1731)
- Scott Keith
- Krupa Gandhi (ORCID: https://orcid.org/0009-0005-7697-0403)
- C. Steinbock-Malfer
- W. Kevin Kelly
- Nikita Nikita
- Swapnil Sharma
- Stephen J Freedland
Institutions
- Cedars-Sinai Medical Center (US)
- Thomas Jefferson University (US)
- Sidney Kimmel Cancer Center (US)
- Durham VA Medical Center (US)
- Drexel University (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1093/jnci/djag061
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00